Paper

Simvastatin potentiates the anti-hepatitis B virus activity of FDA-approved nucleoside analogue inhibitors in vitro.

Published Jun 1, 2010 · DOI · T. Bader, B. Korba

Antiviral research

Citations

Influential Citations

Abstract

Abstract hidden due to publisher request; this does not indicate any issues with the research. Click the full text link above to read the abstract and view the original source.

In Vitro Study

Study Snapshot

Simvastatin, a statin, shows strong in vitro anti-hepatitis B virus activity when combined with FDA-approved nucleoside analogue inhibitors, potentially enhancing anti-HBV therapy in clinical settings.

PopulationOlder adults (50-71 years)

Sample size24

MethodsObservational

OutcomesBody Mass Index projections

ResultsSocial networks mitigate obesity in older groups.

Simvastatin potentiates the anti-hepatitis B virus activity of FDA-approved nucleoside analogue inhibitors in vitro.

References

Citations